Acquired in-process research and development nm nm
Selling, general and administrative 31.0 % 32.7 %
Income From Operations (29.1)% 26.0 %
Interest expense 345.8 % 336.0 %
Other income, net (3.1)% 42.5 %
Income Before Income Taxes (61.6)% 4.8 %
Income tax expense (42.5)% 11.0 %
Net Income (68.1)% 2.7 %
Earnings Per Common Share:
Basic (67.8)% 3.2 %
Diluted (67.8)% 4.0 %
Weighted Average Common Shares Outstanding:
Basic (0.8)% (0.8)%
Diluted (1.0)% (1.0)%
A -- Includes inventory step-up charge of $53,113 and intangible assets
amortization of $34,940 related to the Mayne Pharma acquisition;
charges of $33,434 related to the planned closures of the Donegal,
Ireland; Ashland, OH; Montreal, Canada; and North Chicago, IL
facilities as part of Hospira's manufacturing optimization
initiatives; a reduction of the obligation associated with the 2005
sale of the Salt Lake City manufacturing plant to ICU Medical
($1,579); and Mayne Pharma integration charges of $6,173.
B -- Acquisition integration charges.
C -- Acquired in-process research and development related to the
acquisition of Mayne Pharma.
D -- Other acquisition-related charge: bridge loan fees incurred as a
result of the Mayne Pharma acquisition expensed upon refinancing of
|SOURCE Hospira, Inc.|
Copyright©2007 PR Newswire.
All rights reserved